MARKET

NVRO

NVRO

Nevro Corp
NYSE
46.60
-0.75
-1.58%
After Hours: 46.60 0 0.00% 17:00 09/30 EDT
OPEN
47.54
PREV CLOSE
47.35
HIGH
49.27
LOW
46.60
VOLUME
418.18K
TURNOVER
0
52 WEEK HIGH
121.78
52 WEEK LOW
39.41
MARKET CAP
1.65B
P/E (TTM)
-11.6977
1D
5D
1M
3M
1Y
5Y
Why Is Nevro (NVRO) Down 1% Since Last Earnings Report?
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/02 15:31
Nevro Wins Multiple Coverage Options For Spinal Cord Stimulation In Diabetic Neuropathy
Benzinga · 09/01 15:19
Nevro Announces Participation In Upcoming Investor Conferences
Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that it is participating in the following investor conferences:
PR Newswire · 08/09 11:00
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
Zacks · 08/05 16:58
Where Nevro Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcom...
Benzinga · 08/04 17:44
--Wells Fargo Securities Adjusts Nevro's Price Target to $86 From $90, Reiterates Overweight Rating
--Wells Fargo Securities Adjusts Nevro's Price Target to $86 From $90, Reiterates Overweight Rating
MT Newswires · 08/04 12:37
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 12.35% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/03 23:25
BRIEF-Nevro Reports Second Quarter 2022 Financial Results
BRIEF-Nevro Reports Second Quarter 2022 Financial Results
Reuters · 08/03 21:39
More
About NVRO
Nevro Corp. is a global medical device company, which is focused on delivering comprehensive, life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system. SCS is a neuromodulation platform for the treatment of chronic pain, with the Senza Omnia platform, which is in addition to the Senza family of products. The Company’s solution for chronic pain includes 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain based on what it believes to be the best clinical evidence available. The advantages of its 10 kHz Therapy over traditional SCS include demonstrated superior efficacy data for both leg and back pain, paresthesia free pain relief for patients, anatomical lead placement for physicians, and ability to treat a broader group of chronic pain patients.

Webull offers kinds of Nevro Corp stock information, including NYSE:NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVRO stock methods without spending real money on the virtual paper trading platform.